Literature DB >> 17418549

Preparation and characterization of a potent, long-lasting recombinant human serum albumin-interferon-alpha2b fusion protein expressed in Pichia pastoris.

Yan-Shan Huang1, Zhi Chen, Zhi-Yu Yang, Tong-Ying Wang, Li Zhou, Jian-Bing Wu, Lin-Fu Zhou.   

Abstract

A long-lasting recombinant human serum albumin-interferon-alpha2b fusion protein (rHSA/IFNalpha2b) was prepared and its structure and biological activities were studied. rHSA/IFNalpha2b was expressed in methylotrophic yeast Pichia pastoris with HSA's natural signal peptide and purified by dye affinity chromatography, hydrophobic interaction chromatography, ion exchange chromatography and Sephadex G25. Purity of the prepared rHSA/IFNalpha2b was greater than 97% analyzed by non-reduced SDS-PAGE and RP-HPLC. Structure and biological activities of the prepared rHSA/IFNalpha2b were characterized by physical, chemical and biological methods. Its pI was 5.3 and showed a single band on IEF gel. Molecular weight determined by MALDI-TOF was 86004.3+/-29.2. Amino-terminal and carboxyl-terminal amino acid sequences were identical to predicted sequence. Its specific activity in vitro was 6.3+/-0.8x10(5) IU/mg fusion protein, retaining about 1.4% of that of unmodified rIFNalpha on a molar basis. After administered in monkeys, significant increases of 2',5'-oligoadenylate synthetase activity relative to IFN-alpha were maintained for 14 days in serum and the rHSA/IFNalpha2b showed more potent biological activity than IFN-alpha on a molar basis. Therefore, markedly improved in vivo biological activity of rHSA/IFNalpha2b could exhibit more potent antiviral activity than IFNalpha2b in future clinical trials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17418549     DOI: 10.1016/j.ejpb.2007.02.015

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  3 in total

1.  Modulation of immunogenicity and immunoprotection of mucosal vaccine against coxsackievirus B3 by optimizing the coadministration mode of lymphotactin adjuvant.

Authors:  Yan Yue; Wei Xu; Sidong Xiong
Journal:  DNA Cell Biol       Date:  2011-10-11       Impact factor: 3.311

Review 2.  IL-1Ra and its delivery strategies: inserting the association in perspective.

Authors:  Muhammad Sajid Hamid Akash; Kanwal Rehman; Shuqing Chen
Journal:  Pharm Res       Date:  2013-06-22       Impact factor: 4.200

3.  Albumin fusion of interleukin-28B: production and characterization of its biological activities and protein stability.

Authors:  Jin Zhao; Youhui Si; Min Cheng; Yang Yang; Yuqiang Niu; Xiang Li; Xiuying Liu; Wei Yang
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.